Verition Fund Management’s Aclaris Therapeutics ACRS Stock Holding History
Bought
Maintained
Sold
Other funds holding ACRS
BCM
Verition Fund Management's ACRS Position: Q3 2026 in Review
Verition Fund Management sold out of Aclaris Therapeutics (ACRS) in Q3 2026, closing a stake of 98,000 shares — an estimated $559K sold.
Verition Fund Management first reported a position in ACRS in Q2 2020 and held it in 14 quarters. The position peaked at $6.75M in Q2 2023. 167 funds tracked by Wall St. Rank hold ACRS as of Q3 2026.
- Verition Fund Management reported no remaining Aclaris Therapeutics position as of Q3 2026 after selling out during the quarter.
- Verition Fund Management sold 98,000 Aclaris Therapeutics shares in Q3 2026, an estimated $559K.
- Verition Fund Management first reported a position in Aclaris Therapeutics in Q2 2020 and held it in 14 quarters.
- Verition Fund Management's Aclaris Therapeutics position peaked at $6.75M in Q2 2023.
- 167 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2026.
Based on Verition Fund Management's 13F filing for Q3 2026, filed 13 Nov 2026.